Health Robotics Reports 36 New Sales and Record 3Q2011 Results; Extends Worldwide, Undefeated, Win Streak to 21+ Months

Oct 03, 2011, 09:00 ET from Health Robotics

BOZEN, Sud-Tirol, Italy, October 3, 2011 /PRNewswire/ --

From a customer perspective, Health Robotics recorded its best-ever global trimester in 3Q2011, notably beginning to harvest benefits from its 1Q2011 decision to enter direct marketing operations in some countries, and persevering with its expense-intensive but essential strategy to replace McKesson in North America, which rapidly yielded 10 USA-based robots now in productive use.

These exceptional 3Q2011 results included 30 new product sales to hospitals [list below] and 6 new product sales to indirect channels with a breakdown of 25 robots and 11 i.v.SOFT units, and reaching well over 200 total installations worldwide. Dating back to December 2009, Health Robotics extended to 21 months its undefeated streak of winning 100% of all I.V. Robots' publicly announced purchases versus our direct competitors[1].

"3Q2011 represents a turning point in the now unquestionable evidence that some of Health Robotics' ex-distributors in Europe and North America had seriously burdened the company with sub-par sales and service performance before 2011; there is simply no other explanation for the explosion in customer satisfaction and marketing success that Health Robotics has experienced after replacing McKesson's installation and technical support resources in the USA, and revamping its marketing channel strategies in certain countries," stated Gaspar DeViedma, Health Robotics' Executive Vice President.

Health Robotics' 30 new hospital sales [22 robots] included 11 CytoCare, 3 i.v.STATION ONCO, 8 i.v.STATION, and 8 i.v.SOFT at Duke University Hospital, Mercy Medical Center in Cedar Rapids, LeeSar Cooperative Services of Florida [Lee Memorial-Sarasota Memorial], Mont-Godinne University Hospital in Yvoir, Saint-Luc University Hospital in Brussels, Nagoya City University Hospital in Japan, American Hospital in Istanbul, Memorial Okmeydani Hospital in Istanbul, Kartal State Hospital in Istanbul, Numune Hospital in Ankara, King Fahad Specialist Hospital in Dammam, King Abdullah Medical City in Mecca, and University Malaya Medical Centre in Kuala Lumpur. Additionally, Health Robotics' had 6 new indirect sales [3 robots] to its exclusive distributors in Canada, Czech Republic, Norway, and Saudi Arabia (Sandoz Canada, S&T, Beckman Automation, and Olayan), including 1 CytoCare, 2 i.v.STATION and 3 i.v.SOFT contracts.

Concluded Mr. DeViedma: "Oncology continues to represent more than 50% of new sales, aided by the fact that our competitors that announced Oncology robots as far back as 22 years ago have yet been unable to demonstrate their robots' productive use anywhere in the world[2] . While Health Robotics' original indirect marketing channel strategy continues to work as designed in Canada, Japan, Kingdom of Saudi Arabia, Malaysia, and Turkey to name a few countries, from now on we will strive to more selectively balance geographical channel strategies between direct and indirect sales, given the recent direct marketing success experienced in a few initial countries. It is our clear objective to start 2012 unencumbered of Health Robotics' few remaining non-performing distribution channels around the world."

About Health Robotics:

Founded in 2006, Health Robotics is the undisputed global leading supplier of life-critical intravenous medication robots, winning 100% of all worldwide I.V. Robot's publicly announced purchases over the past 21 months, and providing over 200 hospital installations in 6 continents with robotics-based technology and clinical software automation solutions. Health Robotics' world-leading solutions CytoCare® and i.v.STATION® ONCO [hazardous IVs], i.v.STATION® [non-hazardous IVs], i.v.SOFT® [workflow engine for sterile compounding], MEDarchiver® [life-critical clinical information system], and TPNstation™ [totally-automated parenteral nutrition] have and will greatly contribute to ease hospitals' growing pressures to improve patient safety, increase throughput and contain costs. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics' products help hospitals eliminate life-threatening drug and diluent exchange errors, decrease other medical mistakes and sterility risks, work more efficiently, reduce waste and controlled substances' diversion, and diminish the gap between rising patient volume/acuity and scarce medical, nursing, and pharmacy staff. For more information, please visit: http://www.health-robotics.com

 

1. "Direct competitors" are all companies in the world that have publicly claimed to have developed I.V. Robots: IHS/RIVA, Baxa/For Health, Medical Dispensing, and Panasonic.

2. Am J Hosp Pharm 46(11): 2286---93, 1989


 

For specific requests, please contact:

Claudia Flaim, Marketing Coordinator
flaim@health-robotics.com
Phone (Canada): +1-289-470-1456
Phone (Europe): +39(0)471-200-372

SOURCE Health Robotics